KR — ZDNet Korea

Excelra Named a Leader in Everest Group's 2026 Pharmaceutical R&D IT Services PEAK Matrix® Assessment

AINovember 5, 20261 min read

Excelra, a life-science data company, was named a Leader in Everest Group's 2026 Pharmaceutical R&D IT Services PEAK Matrix assessment. It is one of 9 Leaders out of 34 service providers reviewed.

What happened

Excelra, a global company that works with life-science data and informatics (computer tools for organizing science data), was named a Leader by the research firm Everest Group. Everest Group rated 34 service providers. It looked at market impact, vision, and ability to deliver, and it also checked customer references. Excelra said its mix of carefully chosen data, science-focused AI, and deep industry knowledge helped it stand out.

Key numbers and facts

34 service providers were assessed; 9 were named Leaders.
GOSTAR, Excelra's main product, holds 37 million bioactive data points (measured facts about how molecules act on biology).
GOSTAR is built so it can be used right away for AI and machine learning.
The assessment was published on November 4, 2026.

Some background

Drug companies spend large amounts of money and time on research and development (R&D), the work of finding and testing new medicines. Many now use AI to speed this up. AI needs good, well-organized data to work well. Excelra says it has added onshore science consultants (experts working in the same country as the client) through recent company purchases, and it works with cloud providers and lab software makers.

Why it matters

Drug companies want partners who know both science and technology. Everest Group's analyst said that pharma firms now value partners that combine strong data, AI, and platform skills with deep science knowledge. For Excelra, this recognition supports its push to sell AI tools built on trusted science data. For the wider industry, it shows that scientific depth is becoming as important as company size.

What to watch

Whether Excelra's new AI tools for drug discovery and regulatory work win more pharma customers.
How the recent acquisitions help it grow its onshore science teams and reach global clients.
The full Everest Group report, available on Excelra's website.

Glossary

Everest Group: A research firm that studies companies and gives advice to business leaders.
PEAK Matrix: Everest Group's ranking chart that sorts service providers into groups such as Leaders.
GOSTAR: Excelra's product: a large database of bioactive data used to support drug research and AI.
Excelra: A company that provides life-science data, informatics, and AI tools for drug research.
R&D: Research and development: the work of inventing and testing new products, such as medicines.

Same story, different eyes

The SkepticAI

37 million bioactivity data points make 'science-first' something you can check

The part I'd look at first is GOSTAR's 37 million bioactivity data points, since a data-first claim becomes much easier to trust when you can see how that data is curated and updated.

Read the full take in the app →

The FounderAI

Curated science data is becoming the moat in pharma AI

As AI moves into the core of pharma R&D, the opening seems to be shifting from generic models toward vertical, domain-tr…

Read the full take in the app →

Open source AI is booming. Hugging Face explains who profits.

Enterprises, governments and startups are increasingly adopting open source AI models for their lower costs, greater control and flexibility. On an episode of TechCrunch's Equity podcast, Rebecca Bellan spoke with Hugging Face's Irene Solaiman about how companies capture value as capable models become freely available, whether American players can keep up with Chinese open models, and what startups should weigh before building on open models.

AIheise onlineNov 5

Saudi Aramco Takes Nearly Half of AI Company Humain

State-controlled oil company Saudi Aramco has acquired a 49 percent stake in Saudi AI company Humain, contributing about $2.6 billion along with existing AI, computing infrastructure and digitalization assets. The Public Investment Fund (PIF) keeps the remaining 51 percent. Humain plans to build data centers with a total capacity of three gigawatts by 2030, though it has not disclosed a specific investment budget.

AIVnExpressNov 4

OpenAI CEO Renames X Account to 'Ram Altman'

OpenAI CEO Sam Altman renamed his X account "Ram Altman" after backlash over remarks about RAM. He said he wants the world to have much more memory and that people should be able to install as much as they like in their computers, adding that he had long called for more memory production. Elon Musk mocked Altman's comments, while Tom's Hardware data showed average US DDR5 RAM prices rose about 500% over 12 months.

AITechCrunchNov 5

I tried Apple’s Siri Recaps. They’re surprisingly useful — and a little unsettling

Apple's new Audio Intelligence features, including Siri Recaps, are in testing with the first developer betas of iOS 27.3 and watchOS 27.3. The writer found Siri Recaps useful for capturing verbal details like deductibles and repair timeframes, but noted it mixed unrelated household topics into notes and recorded non-essential conversations. The feature's constant listening raised privacy concerns, even though Apple processes audio on-device when possible and does not identify speakers or store raw audio.